Conba Pharmaceutical shareholder completes stake reduction ahead of Q3 earnings call

Zhejiang Conba Pharmaceutical announced its 5% shareholder, Conba Group, completed a share reduction of 25,242,600 shares between October 23 and November 11, 2025. This represents 1.000% of the company's total share capital at the time of the reduction plan's disclosure, or 0.999% of the current total share capital. The shares were sold via centralized bidding at prices ranging from CNY 4.50 to CNY 4.81 per share, totaling CNY 117,710,220.

Following the transaction, Conba Group and its parties acting in concert, Hu Jiqiang, collectively hold 323,188,576 shares, or 12.792% of the company's current total share capital. The reduction was undertaken to meet Conba Group's business development funding needs.

Zhejiang Conba Pharmaceutical will hold a Q3 earnings briefing on November 19, 2025, from 2:00 PM to 3:00 PM, accessible via the Shanghai Stock Exchange Roadshow Center website. Investors can submit questions in advance from November 12 to November 18, 2025.